Read More Pharma Industry News Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry? bySrinathOctober 24, 2025